.png){kind=icon}
.png){kind=icon}
Return
Direct-Acting Antiviral Therapy and Long-Term Outcomes in Dialysis Patients With Hepatitis C: A Real-world Cohort Study
.png){kind=icon}
OA
AI
M
J
Y
T
DOI：10.1093/ofid/ofag389.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hepatitis C virus (HCV) infection is associated with adverse outcomes among patients with end-stage kidney disease (ESKD) receiving dialysis. Although direct-acting antivirals (DAAs) achieve high cure rates in patients with ESKD, real-world evidence regarding their long-term clinical benefits remains limited. We evaluated the association between direct-acting antiviral (DAA) therapy and long-term outcomes among dialysis patients with HCV infection.
Journal
IF:
3.8
Papers:
6.3K
Citations:
1.4W
Organization
Cited Papers